News & Updates

Circulating tumour DNA (ctDNA) testing after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) may inform patients with muscle-invasive bladder cancer (MIBC) of their risk for recurrence and allows personalized postoperative management in MIBC, results of the TOMBOLA trial have shown.

Excessive intrahepatic fat deposition (IPFD) appears to contribute to an increased risk of major pancreatic disease, suggests a recent study, noting the potential benefits of IPFD reduction in preventing pancreatitis and pancreatic cancer.

Management of metastatic hormone-sensitive prostate cancer (mHSPC) continues to evolve as clinicians refine the use of androgen deprivation therapy (ADT) and/or chemotherapy in combination with androgen receptor pathway inhibitors (ARPIs) in routine clinical practice. At an advisory board meeting organized by the Hong Kong Society of Uro-Oncology, Professor Axel Merseburger of the University of Lübeck in Germany and Dr Darren Poon of the Hong Kong Sanatorium & Hospital discussed updated strategies and shared case studies to illustrate use of optimal ARPI-based regimens in patients with mHSPC.

Prostate cancer patients treated with enzalutamide plus leuprolide have a higher probability of remaining free of distant metastasis, castration resistance, symptomatic progression, and first symptomatic skeletal event (SSE) at 5 years than those treated with leuprolide alone, as shown by the results of the EMBARK study.